摘要
目的观察调强放疗联合化疗对晚期宫颈癌治疗效果及血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC)水平的影响。方法选取2018年1月—2020年12月就诊的102例晚期宫颈癌为研究对象,根据治疗方式不同分为对照组49例和研究组53例,对照组采用常规放疗联合化疗,研究组采用调强放疗联合化疗。比较两组临床疗效,以及治疗前后血清CYFRA21-1和SCC水平、癌症治疗功能总体评价量表(FACT-G)评分,并观察两组毒副反应发生情况。结果研究组临床总有效率高于对照组(P<0.05)。治疗1、3个月后两组血清CYFRA21-1、SCC水平均较治疗前下降,FACT-G评分均较治疗前升高(P<0.05)。治疗3个月后研究组血清CYFRA21-1、SCC水平低于对照组,FACT-G评分高于对照组(P<0.05)。研究组白细胞下降、骨髓抑制、放射性膀胱炎、放射性直肠炎发生率低于对照组(P<0.05)。结论对晚期宫颈癌患者采取调强放疗联合化疗能够有效提高治疗效果,降低血清CYFRA21-1、SCC水平和毒副反应发生率。
Objective To observe clinical efficacy of intensity-modulated radiotherapy(IMRT)combined with chemotherapy in treatment of patients with advanced cervical cancer and its effects on serum levels of cytokeratin fragment antigen 21-1(CYFRA21-1)and squamous cell carcinoma antigen(SCCA).Methods A total of 102 patients with advanced cervical cancer between January 2018 and December 2020 were selected and divided into control group(n=49)and research group(n=53)according to different therapeutic methods.Control group was treated with conventional radiotherapy combined with chemotherapy,while research group was treated with IMRT combined with chemotherapy.Clinical efficacy,serum levels of CYFRA21-1 and SCCA,and functional assessment of cancer therapy-general(FACT-G)score before and after treatment were compared,and conditions of toxic and side effects were observed in two groups.Results The total clinical effective rate in research group was significantly higher than that in control group(P<0.05).After treatment for 1 and 3 months,serum levels of CYFRA21-1 and SCCA were significantly lower,while FACT-G scores were significantly higher than those before treatment in two groups(P<0.05).Compared with those in control group,serum levels of CYFRA21-1 and SCCA were significantly lower,while FACT-G score was significantly higher after treatment for 3 months in research group(P<0.05).Incidence rates of leukopenia,bone marrow suppression,radiation cystitis and radiation proctitis in research group were significantly lower than those in control group(P<0.05).Conclusion IMRT combined with chemotherapy in treatment of patients with advanced cervical cancer may effectively improve clinical efficacy,reduce serum levels of CYFRA21-1 and SCCA and incidence rates of toxic and side effects.
作者
颜春晓
法静
YAN Chun-xiao;FA Jing(The Second Department of Gynecology,Linyi Tumor Hospital,Linyi,Shandong 276000,China)
出处
《临床误诊误治》
CAS
2022年第5期58-61,共4页
Clinical Misdiagnosis & Mistherapy
基金
山东省医药卫生科技发展计划项目(2016WS0246)。
关键词
宫颈肿瘤
放射疗法
调强适形
联合化疗
治疗效果
细胞角蛋白19片段抗原21-1
鳞状细胞癌抗原
Uterine cervical neoplasms
Radiotherapy,intensity-modulated
Combination chemotherapy
Treatment effectiveness
Cytokeratin fragment antigen 21-1
Squamous cell carcinoma antigen
